179 related articles for article (PubMed ID: 33637349)
1. REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer.
Sjoquist KM; Espinoza D; Mileshkin L; Ananda S; Shannon C; Yip S; Goh J; Bowtell D; Harrison M; Friedlander ML
Gynecol Oncol; 2021 May; 161(2):374-381. PubMed ID: 33637349
[TBL] [Abstract][Full Text] [Related]
2. A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites.
Colombo N; Mangili G; Mammoliti S; Kalling M; Tholander B; Sternas L; Buzenet G; Chamberlain D
Gynecol Oncol; 2012 Apr; 125(1):42-7. PubMed ID: 22112608
[TBL] [Abstract][Full Text] [Related]
3. The usefulness of bevacizumab for relief from symptomatic malignant ascites in patients with heavily treated recurrent ovarian cancer.
Shimizu Y; Kajiyama H; Yoshida K; Tamauchi S; Nakanishi T; Kikkawa F
J Obstet Gynaecol Res; 2019 Dec; 45(12):2435-2439. PubMed ID: 31468618
[TBL] [Abstract][Full Text] [Related]
4. Intraperitoneal administration of cisplatin plus bevacizumab for the management of malignant ascites in ovarian epithelial cancer: results of a phase III clinical trial.
Zhao H; Li X; Chen D; Cai J; Fu Y; Kang H; Gao J; Gao K; Du N
Med Oncol; 2015 Feb; 32(2):292. PubMed ID: 25609006
[TBL] [Abstract][Full Text] [Related]
5. Intraperitoneal pressures and clinical parameters of total paracentesis for palliation of symptomatic ascites in ovarian cancer.
Gotlieb WH; Feldman B; Feldman-Moran O; Zmira N; Kreizer D; Segal Y; Elran E; Ben-Baruch G
Gynecol Oncol; 1998 Dec; 71(3):381-5. PubMed ID: 9887235
[TBL] [Abstract][Full Text] [Related]
6. Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer.
Hamilton CA; Maxwell GL; Chernofsky MR; Bernstein SA; Farley JH; Rose GS
Gynecol Oncol; 2008 Dec; 111(3):530-2. PubMed ID: 18561992
[TBL] [Abstract][Full Text] [Related]
7. Safety, cost-effectiveness and feasibility of daycase paracentesis in the management of malignant ascites with a focus on ovarian cancer.
Harding V; Fenu E; Medani H; Shaboodien R; Ngan S; Li HK; Burt R; Diamantis N; Tuthill M; Blagden S; Gabra H; Urch CE; Moser S; Agarwal R
Br J Cancer; 2012 Sep; 107(6):925-30. PubMed ID: 22878372
[TBL] [Abstract][Full Text] [Related]
8. Outcomes and prognoses of patients with ovarian cancer using bevacizumab: 6-year experience in a tertiary care hospital of northern Taiwan.
Chen WC; Qiu JT; Lai CH; Huang HJ; Lin CT; Chen MY; Chou HH; Huang KG; Chang TC
PLoS One; 2017; 12(5):e0175703. PubMed ID: 28467466
[TBL] [Abstract][Full Text] [Related]
9. Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study.
Gotlieb WH; Amant F; Advani S; Goswami C; Hirte H; Provencher D; Somani N; Yamada SD; Tamby JF; Vergote I
Lancet Oncol; 2012 Feb; 13(2):154-62. PubMed ID: 22192729
[TBL] [Abstract][Full Text] [Related]
10. Intraperitoneal bevacizumab for control of malignant ascites due to advanced-stage gastrointestinal cancers: A multicentre double-blind, placebo-controlled phase II study - AIO SUP-0108.
Jordan K; Luetkens T; Gog C; Killing B; Arnold D; Hinke A; Stahl M; Freier W; Rüssel J; Atanackovic D; Hegewisch-Becker S
Eur J Cancer; 2016 Aug; 63():127-34. PubMed ID: 27314448
[TBL] [Abstract][Full Text] [Related]
11. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial.
Heiss MM; Murawa P; Koralewski P; Kutarska E; Kolesnik OO; Ivanchenko VV; Dudnichenko AS; Aleknaviciene B; Razbadauskas A; Gore M; Ganea-Motan E; Ciuleanu T; Wimberger P; Schmittel A; Schmalfeldt B; Burges A; Bokemeyer C; Lindhofer H; Lahr A; Parsons SL
Int J Cancer; 2010 Nov; 127(9):2209-21. PubMed ID: 20473913
[TBL] [Abstract][Full Text] [Related]
12. A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma.
Brandes AA; Gil-Gil M; Saran F; Carpentier AF; Nowak AK; Mason W; Zagonel V; Dubois F; Finocchiaro G; Fountzilas G; Cernea DM; Chinot O; Anghel R; Ghiringhelli F; Beauchesne P; Lombardi G; Franceschi E; Makrutzki M; Mpofu C; Urban HJ; Pichler J
Oncologist; 2019 Apr; 24(4):521-528. PubMed ID: 30266892
[TBL] [Abstract][Full Text] [Related]
13. Atezolizumab and Bevacizumab Attenuate Cisplatin Resistant Ovarian Cancer Cells Progression Synergistically via Suppressing Epithelial-Mesenchymal Transition.
Zhang L; Chen Y; Li F; Bao L; Liu W
Front Immunol; 2019; 10():867. PubMed ID: 31105696
[TBL] [Abstract][Full Text] [Related]
14. A randomized trial of paracentesis plus intraperitoneal tumor necrosis factor-alpha versus paracentesis alone in patients with symptomatic ascites from recurrent ovarian carcinoma.
Hirte HW; Miller D; Tonkin K; Findlay B; Capstick V; Murphy J; Buckman R; Carmichael J; Levine M; Hill W
Gynecol Oncol; 1997 Jan; 64(1):80-7. PubMed ID: 8995552
[TBL] [Abstract][Full Text] [Related]
15. Randomized prospective trial of fractionated stereotactic radiosurgery with chemotherapy versus chemotherapy alone for bevacizumab-resistant high-grade glioma.
Bergman D; Modh A; Schultz L; Snyder J; Mikkelsen T; Shah M; Ryu S; Siddiqui MS; Walbert T
J Neurooncol; 2020 Jun; 148(2):353-361. PubMed ID: 32444980
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Procedures for Malignant Ascites in a Palliative Care Outpatient Clinic.
Korpi S; Salminen VV; Piili RP; Paunu N; Luukkaala T; Lehto JT
J Palliat Med; 2018 Jun; 21(6):836-841. PubMed ID: 29489450
[TBL] [Abstract][Full Text] [Related]
17. Long-term survival with bevacizumab in heavily pretreated and platinum-resistant mucinous ovarian cancer: A case report.
Tarumi Y; Mori T; Matsushima H; Kokabu T; Tsuchiya H; Kitawaki J
J Obstet Gynaecol Res; 2018 Feb; 44(2):347-351. PubMed ID: 29121427
[TBL] [Abstract][Full Text] [Related]
18. Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of Müllerian origin.
Krasner CN; Castro C; Penson RT; Roche M; Matulonis UA; Morgan MA; Drescher C; Armstrong DK; Wolfe JK; Lee H; Supko JG; Seiden M; Birrer MJ; Dizon DS
Gynecol Oncol; 2019 May; 153(2):223-229. PubMed ID: 30765148
[TBL] [Abstract][Full Text] [Related]
19. Current and future options in the treatment of malignant ascites in ovarian cancer.
Woopen H; Sehouli J
Anticancer Res; 2009 Aug; 29(8):3353-9. PubMed ID: 19661355
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of cediranib as palliative treatment in patients with symptomatic malignant ascites or pleural effusion.
Mulder SF; Boers-Sonderen MJ; van der Heijden HF; Vissers KC; Punt CJ; van Herpen CM
Target Oncol; 2014 Dec; 9(4):331-8. PubMed ID: 24446026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
